BioNTech's AGM Unlocks $1 Billion Buyback and Cancer-Focused Board as Clinical Data Deadline Nears

Shareholders unanimously backed board expansion to eight with oncology experts, a $1B buyback, and retained earnings. Q1 revenue fell to €118M, net loss widened to €531.9M. Pumitamig Phase 2 data at ASCO is key catalyst.

Shareholders of BioNTech handed management an unusually unified mandate at this month’s virtual annual general meeting, approving every item on the agenda without a single dissenting vote. With 92% of the share capital represented on 15 May, the show of support came as the stock trades just a whisker above its 52-week low — a gap that underscores how far the company’s ambitions have outpaced its market valuation.

The most consequential corporate move to emerge from the gathering is a board expansion from six to eight members. Two new oncology specialists — Prof. Iris Löw-Friedrich and Susanne Schaffert — join the supervisory board, while Helmut Jeggle immediately assumed the chairmanship. The additions are designed to bring deeper clinical development and commercial expertise into the governance layer as BioNTech pivots away from its COVID-vaccine dependence. Sitting directors Prof. Anja Morawietz and Prof. Rudolf Staudigl also secured fresh mandates.

Alongside the governance reshuffle, shareholders authorised a share buyback programme of up to $1 billion over the coming twelve months — first flagged on 7 May. The company will fund the repurchases out of its cash pile, which stood at roughly €16.8 billion at the end of the first quarter. No dividend was declared; instead, all retained earnings of around €6.9 billion remain inside the business to fuel the pipeline and the buyback.

The AGM also approved a new Authorised Capital 2026 — capable of covering up to half of the current share capital — and a profit-and-loss transfer agreement for BioNTech Discovery GmbH. Though technical in nature, the latter allows the parent to offset group losses against subsidiary profits, a strategic move that conserves financial flexibility during the heavy research spend of the oncology shift.

That spending is already drawing deeply on the balance sheet. BioNTech’s first-quarter results, released ten days before the meeting, showed revenue falling to €118 million from €182.8 million a year earlier. The net loss widened to €531.9 million as COVID-vaccine sales evaporated. Management nevertheless stuck to its 2026 revenue target of between €2.0 billion and €2.3 billion — a goal that hinges entirely on the success of its oncology pipeline.

Chief executive Ugur Sahin used the AGM to reinforce that message, pointing to more than 25 ongoing Phase 2 and Phase 3 studies and 17 clinical programmes. The flagship candidate, pumitamig, a bispecific immune modulator, has now shown activity across multiple tumour types. Five registration trials are already underway, some in collaboration with Bristol Myers Squibb. In a lung-cancer study, pumitamig is being tested head-to-head against pembrolizumab, and Phase 2 data from that trial will be presented at the American Society of Clinical Oncology congress later this month.

The ASCO readout represents the most immediate catalyst for the stock. Positive results could narrow the yawning gap between analyst sentiment and market price. Fifteen of the nineteen analysts covering BioNTech rate the shares a strong buy, with a consensus price target of $135.84. Berenberg, while trimming its own target on 12 May, continues to describe the stock as deeply undervalued.

Yet the secondary-market verdict has been far less enthusiastic. The shares closed last Friday at €77.10, shedding 2.03% on the day and leaving them roughly 11% below their 200-day moving average. That price is only about 6% above the March trough of €72.50, which followed the announcement that both co-founders would depart. The wide dispersion in analyst targets — ranging from $94 to $171 — reflects how much the valuation hangs on coming data.

For now, BioNTech has the shareholder backing, the cash, and the clinical breadth to make its case. The next few weeks will determine whether the market is ready to listen.